251
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study

, , , , , , , & show all
Pages 163-168 | Received 05 Dec 2019, Accepted 06 Jan 2020, Published online: 26 Jan 2020

References

  • Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–1725.
  • Choi CH, Moon W, Kim YS, et al. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15(1):7–37.
  • Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
  • (a) Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5:477–483; (b) Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis Gastroenterology. 2011;141:1194–1201; (c) Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2016;22:1859–1869.
  • (a) Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851–1858; (b) D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
  • Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110(6):873–880.
  • Shi HY, Chan FKL, Chan AWH, et al. Accuracy of faecal immunochemical test to predict endoscopic and histological healing in ulcerative colitis: a prospective study based on validated histological scores. J Crohns Colitis. 2017;11(9):1071–1077.
  • Ma C, Lumb R, Walker EV, et al. Noninvasive fecal immunochemical testing and fecal calprotectin predict mucosal healing in inflammatory bowel disease: a prospective cohort study. Inflamm Bowel Dis. 2017;23(9):1643–1649.
  • Mooiweer E, Fidder HH, Siersema PD, et al. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2014;20(2):307–314.
  • Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18(9):1634–1640.
  • Shi HY, Chan FKL, Tsang SWC, et al. Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2015;21(4):840–846.
  • von Martels JZH, Bourgonje AR, Harmsen HJM, et al. Assessing intestinal permeability in Crohn’s disease patients using orally administered 52Cr-EDTA. PLoS One. 2019;14(2):e0211973.
  • Kato J, Hiraoka S, Nakarai A, et al. Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res. 2016;14(1):5–14.
  • Nakarai A, Hiraoka S, Takahashi S, et al. Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse. J Crohns Colitis. 2018;12(1):71–76.
  • (a) Sandborn WJ, Colombel JF, Ghosh S, et al. Eldelumab [anti-IP-10] induction therapy for ulcerative colitis: a randomised, placebo-controlled, phase 2b study. J Crohns Colitis. 2016;10:418–428; (b) Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147:1296–1307 e1295; (c) Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109:1771–1780.
  • (a) Boal Carvalho P, Dias de Castro F, Rosa B, et al.. Mucosal healing in ulcerative colitis–when zero is better.J Crohns Colitis. 2016;10:20–25; (b) Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (mayo 0 vs 1): a longitudinal cohort study. J Crohns Colitis. 2016;10:13–19.
  • Hiraoka S, Kato J, Nakarai A, et al. Consecutive measurements by faecal immunochemical test in quiescent ulcerative colitis patients can detect clinical relapse. J Crohns Colitis. 2016;10(6):687–694.
  • Patel A, Panchal H, Dubinsky MC. Fecal calprotectin levels predict histological healing in ulcerative colitis. Inflamm Bowel Dis. 2017;23(9):1600–1604.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.